Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$10.00 +3.0%	$9.65	$2.20 ▼ $12.78	$273.90M	-0.59	192,294 shs	55,371 shs
INZY Inozyme Pharma	$4.00	$3.76	$0.72 ▼ $6.24	$258.25M	2.27	953,803 shs	N/A
LFCR Lifecore Biomedical	$7.49 -2.5%	$7.29	$3.68 ▼ $8.85	$277.32M	0.71	229,200 shs	118,062 shs
MCRB Seres Therapeutics	$14.07 -0.1%	$9.14	$6.53 ▼ $29.40	$122.86M	2.75	129,203 shs	85,712 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	+2.99%	-7.41%	+1.52%	+25.31%	+150.00%
INZY Inozyme Pharma	0.00%	0.00%	+0.50%	+335.02%	-30.31%
LFCR Lifecore Biomedical	-2.47%	-9.76%	+11.62%	+16.85%	+34.71%
MCRB Seres Therapeutics	-0.07%	+11.93%	+82.02%	+90.14%	-52.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.9521 of 5 stars	4.4	5.0	0.0	2.0	2.5	0.6
INZY Inozyme Pharma	2.8923 of 5 stars	4.2	4.0	0.0	0.0	2.5	0.0
LFCR Lifecore Biomedical	0.7543 of 5 stars	1.3	1.0	0.0	0.6	4.2	0.6
MCRB Seres Therapeutics	2.8881 of 5 stars	2.9	1.0	4.6	1.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	47.50% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	6.81% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	423.57% Upside

Current Analyst Ratings Breakdown

Latest MCRB, INZY, DBVT, and LFCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$4.15M	66.00	N/A	N/A	$1.42 per share	7.04
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
LFCR Lifecore Biomedical	$128.26M	2.16	N/A	N/A	$0.37 per share	20.24
MCRB Seres Therapeutics	$126.32M	0.97	N/A	N/A	$1.61 per share	8.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)

Latest MCRB, INZY, DBVT, and LFCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.0250	N/A	N/A	N/A	$35.36 million	N/A
8/12/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	0.72	0.72
INZY Inozyme Pharma	0.65	2.19	2.19
LFCR Lifecore Biomedical	66.36	2.71	1.59
MCRB Seres Therapeutics	N/A	2.11	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
INZY Inozyme Pharma	88.30%
LFCR Lifecore Biomedical	83.36%
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
INZY Inozyme Pharma	12.18%
LFCR Lifecore Biomedical	32.20%
MCRB Seres Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable

MCRB, INZY, DBVT, and LFCR Headlines

Recent News About These Companies

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Above Fifty Day Moving Average - What's Next?

July 5, 2025 | marketbeat.com

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025 | globenewswire.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

May 23, 2025 | zacks.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

May 16, 2025 | zacks.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript

May 9, 2025 | insidermonkey.com

Chardan Capital Downgrades Seres Therapeutics (MCRB)

May 9, 2025 | msn.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97

May 7, 2025 | msn.com

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Seres Therapeutics Q1 2025 Earnings Preview

May 6, 2025 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%

May 6, 2025 | aaii.comA

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025 | globenewswire.com

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split

April 24, 2025 | bizjournals.com

Seres Therapeutics trading resumes

April 24, 2025 | markets.businessinsider.com

Seres Therapeutics trading halted, volatility trading pause

April 24, 2025 | markets.businessinsider.com

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

April 23, 2025 | globenewswire.com

Seres Therapeutics trading halted, news pending

April 22, 2025 | markets.businessinsider.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 10.81%

April 21, 2025 | aaii.comA

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

April 17, 2025 | zacks.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 7.28%

April 14, 2025 | aaii.comA

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript

March 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, INZY, DBVT, and LFCR Company Descriptions

DBV Technologies NASDAQ:DBVT

$10.00 +0.29 (+2.99%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$10.30 +0.30 (+3.00%)

As of 07/18/2025 07:20 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Lifecore Biomedical NASDAQ:LFCR

$7.49 -0.19 (-2.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.49 0.00 (0.00%)

As of 07/18/2025 04:04 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Seres Therapeutics NASDAQ:MCRB

$14.07 -0.01 (-0.07%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.80 +0.73 (+5.22%)

As of 07/18/2025 07:50 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time